We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Radium-223: Role of Bone Metastases in Castration-Resistant Prostate Cancer.
- Authors
Cassinello, Javier; Chara, Luis; Caviedes, Edinson
- Abstract
Bone metastases occur in over 90% of patients with castration-resistant prostate cancer. The development of skeletal-related events diminishes the quality of life of patients and is associated with increased mortality. Denosumab has been shown to be superior to zoledronic acid in delaying the onset and development of skeletal-related events and is devoid of renal toxicity, so it is preferred in these patients. However, neither of these two compounds has an impact on overall survival. Radium-223, an alpha particle emitter radiopharmaceutical, has shown to increase overall survival versus placebo in these patients and to reduce and delay the onset of skeletal-related events. Due to its very good tolerance, the combination of radium-223 with docetaxel and other agents is under investigation.
- Subjects
BONE metastasis; RADIUMTHERAPY; PROSTATE cancer risk factors; MONOCLONAL antibodies; ZOLEDRONIC acid; QUALITY of life; PHYSIOLOGY; DISEASE risk factors
- Publication
Cancer & Chemotherapy Reviews, 2015, Vol 10, Issue 1, p3
- ISSN
1885-740X
- Publication type
Article